← Search & browse all drugs

ferumoxsil

V08CB01

Forms & Strengths

Oral suspension containing silicone-coated superparamagnetic iron oxide particles
Concentration equivalent to 0.75 mg/mL Fe (approximate magnetic resonance imaging contrast agent)

Adult Dosing

Diagnostic MRI preparation: 15 to 30 mL of oral suspension diluted in water or juice
Administered orally approximately 15 to 30 minutes prior to magnetic resonance imaging of the abdomen or gastrointestinal tract

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established
Use in children is generally off-label and requires specialized institutional protocols if utilized

Indications

Contrast agent for magnetic resonance imaging (MRI) of the gastrointestinal tract
Delineation of the bowel from surrounding abdominal and pelvic organs to improve diagnostic accuracy

Mechanism of Action

Superparamagnetic iron oxide particles shorten T1, T2, and T2* relaxation times of protons in the gastrointestinal lumen
Produces marked signal loss (darkening) on T2-weighted and gradient-echo MRI sequences, reducing bowel motion artifacts and distinguishing bowel loops from adjacent pathology

Contraindications

Known hypersensitivity to iron oxide or any component of the suspension
Patients with severe iron overload disorders (e.g., hemochromatosis)

Adverse Reactions

Mild and transient gastrointestinal disturbances including nausea, diarrhea, and abdominal pain or cramping
Dark or black stools secondary to unabsorbed iron content
Rare allergic or hypersensitivity skin reactions

Drug Interactions

May potentially decrease the oral absorption of concurrently administered medications due to binding by iron oxide particles
No significant systemic pharmacokinetic drug-is interactions expected due to minimal gastrointestinal absorption

Curated Content: Needs Vetting Before Put to Clinical Use